3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
3
poly ICLC
2
fludarabine
2
belinostat
2
aflibercept
2
Radiosurgery
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Docetaxel
2
Cyclophosphamide
2
Carboplatin
2
vocimagene amiretrorepvec
1
tremelimumab
1
trastuzumab deruxtecan
1
seribantumab
1
rucaparib
1
romidepsin
1
resiquimod
1
palbociclib
1
etoposide phosphate
1
entinostat
1
durvalumab
1
ciforadenant
1
cemiplimab
1
cc-486
1
avelumab
1
amminedichloro(2-methylpyridine)platinum(II)
1
Trastuzumab
1
Thalidomide
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Radionuclide Imaging
×
Sarcoma
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled